No Data
No Data
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug
Express News | Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (Maa) and Orphan Drug Designation (Odd) for Paltusotine in Acromegaly
J.P. Morgan Maintains Crinetics(CRNX.US) With Buy Rating, Announces Target Price $53
JP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics' Atumelnant Data
Stifel Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $60
Express News | Crinetics Pharmaceuticals Inc : JP Morgan Cuts Target Price to $53 From $57